keyword
MENU ▼
Read by QxMD icon Read
search

renal cell carcinoma

keyword
https://www.readbyqxmd.com/read/29470157/solid-small-renal-mass-without-gross-fat-ct-criteria-for-achieving-excellent-positive-predictive-value-for-renal-cell-carcinoma
#1
Sung Yoon Park, Su-Jin Shin, Nam Hoon Cho, Dae Chul Jung, Koon Ho Rha, Woong Kyu Han, Young Taik Oh
OBJECTIVE: The purpose of this study was to evaluate CT criteria for achieving high positive predictive value (PPV) for renal cell carcinoma (RCC) in patients with solid small renal masses (SRMs) less than 4 cm without macroscopic fat. MATERIALS AND METHODS: One hundred fifty consecutive patients with a solid SRM without macroscopic fat (mean size ± SD, 2.5 ± 0.8 cm) who underwent CT including unenhanced, corticomedullary (CMP), and nephrographic phases (NP) were evaluated...
February 22, 2018: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/29468281/-current-guideline-oriented-follow-up-of-small-renal-masses-applied-risk-scores-and-future-outlook
#2
REVIEW
V Stühler, S Kruck, T Todenhöfer, A Stenzl, J Bedke
After surgical resection of renal cell carcinoma by laparoscopic or open partial or complete nephrectomy, medical aftercare based on the current guidelines should be provided. This seems desirable, especially because one third of patients after initial curative tumor resection develop recurrence over time. In this article, the current recommendations for follow-up will be systematically presented based on the accepted German S3 guideline and the European Association of Urology (EAU) guideline. Another point of this article will be the presentation of the currently applied risk scores to predict prognosis with a focus on molecular markers...
February 21, 2018: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/29468160/adhesion-gpcrs-in-kidney-development-and-disease
#3
REVIEW
Salvador Cazorla-Vázquez, Felix B Engel
Chronic kidney disease (CKD) represents the fastest growing pathology worldwide with a prevalence of >10% in many countries. In addition, kidney cancer represents 5% of all new diagnosed cancers. As currently no effective therapies exist to restore kidney function after CKD- as well as cancer-induced renal damage, it is important to elucidate new regulators of kidney development and disease as new therapeutic targets. G protein-coupled receptors (GPCRs) represent the most successful class of pharmaceutical targets...
2018: Frontiers in Cell and Developmental Biology
https://www.readbyqxmd.com/read/29468108/nivolumab-in-renal-cell-carcinoma-current-trends-and-future-perspectives
#4
REVIEW
Cesar E Ochoa, Richard W Joseph
Targeted agents form the backbone of most therapeutic strategies in advanced renal cell carcinoma (aRCC) but ultimately resistance develops and toxicity often leads to discontinuation of treatment, limiting the clinical benefits of these treatments. Nivolumab, a fully human IgG4 anti-PD-1 antibody, selectively blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2 and provides a novel therapy option for patients with aRCC. In 2015, the pivotal phase III study CheckMate 025 led to the Food and Drug Administration approval of nivolumab in patients with aRCC who had received prior anti-angiogenic therapy, and in 2017, the phase III study CheckMate 214 showed that combined immunotherapy with nivolumab plus ipilimumab resulted in greater objective response rate and prolonged progression-free survival when compared with sunitinib in intermediate- and poor-risk patients with previously untreated aRCC...
2018: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/29468097/an-uncommon-case-of-renal-metastasis-from-cervical-cancer
#5
Amine Bazine, Hanae O Zniber, Meriem Ghaouti, Aziz Bazine, Aziz Baydada, Hassan Sifat
Metastases to the kidney are a rare entity. Among solid tumors, it is known that lung and colorectal cancers can metastasize to the kidney. Renal metastases from cervical cancer are exceptional; only 12 cases were previously reported. We report a case of a right renal metastasis from a cervical squamous cell carcinoma, occurring in the context of a metastatic relapse two years after completing primary treatment.
December 13, 2017: Curēus
https://www.readbyqxmd.com/read/29467902/remodeling-and-spacing-factor-1-overexpression-is-associated-with-poor-prognosis-in-renal-cell-carcinoma
#6
Xiuwei Zhang, Dongwei Xue, Fengxia Hao, Lingling Xie, Jiani He, Junda Gai, Yuhui Liu, Hongtao Xu, Qingchang Li, Enhua Wang
The present study aimed to assess the expression and prognostic significance of remodeling and spacing factor 1 (RSF1; HBXAP) in renal cell carcinoma (RCC). RSF1 expression was analyzed using immunohistochemistry on tissue samples from a consecutive series of 137 patients with RCC who underwent tumor resection between November 2000 and March 2004. The associations between RSF1 expression, clinicopathological factors and patient survival were investigated. Immunohistochemistry revealed that RSF1 was highly expressed in 43...
March 2018: Oncology Letters
https://www.readbyqxmd.com/read/29467323/von-hippel-lindau-mutations-disrupt-vascular-patterning-and-maturation-via-notch
#7
Alexandra Arreola, Laura Beth Payne, Morgan H Julian, Aguirre A de Cubas, Anthony B Daniels, Sarah Taylor, Huaning Zhao, Jordan Darden, Victoria L Bautch, W Kimryn Rathmell, John C Chappell
Von Hippel-Lindau (VHL) gene mutations induce neural tissue hemangioblastomas, as well as highly vascularized clear cell renal cell carcinomas (ccRCCs). Pathological vessel remodeling arises from misregulation of HIFs and VEGF, among other genes. Variation in disease penetrance has long been recognized in relation to genotype. We show Vhl mutations also disrupt Notch signaling, causing mutation-specific vascular abnormalities, e.g., type 1 (null) vs. type 2B (murine G518A representing human R167Q). In conditional mutation retina vasculature, Vhl-null mutation (i...
February 22, 2018: JCI Insight
https://www.readbyqxmd.com/read/29466966/real-life-patterns-of-care-and-progression-free-survival-in-metastatic-renal-cell-carcinoma-patients-retrospective-analysis-of-cross-sectional-data
#8
Rana Maroun, Laura Mitrofan, Laure Benjamin, Gaelle Nachbaur, Franck Maunoury, Philippe Le Jeunne, Isabelle Durand-Zaleski
BACKGROUND: Patient characteristics and survival outcomes in randomized trials may be different from those in real-life clinical practice. The objective of this study was to describe treatment pathways, safety, drug costs and survival in patients with metastatic Renal Cell Carcinoma (mRCC) in a real world setting. METHODS: A retrospective analysis was performed using IQVIA real world oncology cross-sectional survey data, a retrospective treatment database collecting anonymized patient-level data in Europe...
February 21, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29465421/molecular-and-metabolic-basis-of-clear-cell-carcinoma-of-the-kidney
#9
Mohammed Akhtar, Issam A Al-Bozom, Turki Al Hussain
Renal cell carcinoma (RCC) is a heterogenous group of tumors, >70% of which belong to the category of clear cell carcinoma. In recent years, crucial advances have been made in our understanding of the molecular and metabolic basis of clear cell carcinoma. This tumor manifests significant alterations in the cellular metabolism, so that the tumor cells preferentially induce the hypoxia response pathway using aerobic glycolysis, rather than the normal oxidative phosphorylation for energy. Most of the clear cell carcinomas (sporadic as well as familial) have mutations and deletions in the VHL gene located at 3p (p3...
February 20, 2018: Advances in Anatomic Pathology
https://www.readbyqxmd.com/read/29464682/comparison-of-partial-and-radical-laparascopic-nephrectomy-long-term-outcomes-for-clinical-t1b-renal-cell-carcinoma
#10
Yi Cai, Han-Zhong Li, Yu-Shi Zhang
PURPOSE: To compare the long-term clinical and oncologic outcomes in patients treated with laparoscopic partial nephrectomy (LPN) and laparoscopic radial nephrectomy (LRN) for clinical T1b renal cell carcinoma. MATERIALS AND METHODS: We retrospectively reviewed the records of all patients who underwent LPN or LRN for a single clinical T1b tumor between January 2005 and January 2012, an actual follow-up of 2-year or greater was available in 39 and 160 after LPN and LRN, respectively...
February 18, 2018: Urology Journal
https://www.readbyqxmd.com/read/29464679/prognostic-significance-of-body-mass-index-and-other-tumor-and-patient-characteristics-in-non-metastatic-renal-cell-carcinoma
#11
Vusal Ahmedov, Fuat Kizilay, Ibrahim Cüreklibatir
PURPOSE: In this retrospective study, we aimed to investigate the prognostic effect of body mass index (BMI) in localized renal cell carcinoma (RCC) cases who underwent surgical treatment. Furthermore, the assessment of various patient and tumor characteristics and surgical methods on survival has been identified as additional targets. MATERIALS AND METHODS: Three hundred and eighty patients with localised, non-metastatic, unilateral RCC who underwent radical or partial nephrectomy in our clinic between January 2007 and December 2016 were enrolled in this study...
February 18, 2018: Urology Journal
https://www.readbyqxmd.com/read/29464464/pazopanib-related-tumor-lysis-syndrome-in-metastatic-clear-cell-renal-cell-carcinoma-a-case-report
#12
Michael W van Kalleveen, Maudy Walraven, Mathijs P Hendriks
Introduction Tumor lysis syndrome (TLS) is a life-threatening emergency caused by rapid cell death as a result of anti-tumor therapy. In the era of targeted therapy it has increasingly been observed in solid malignancies such as hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC). Case We describe the case of a 58-year old man with the medical history of a memorial sloan kettering cancer centre (MSKCC) poor prognosis metastasized clear cell renal cell carcinoma (mRCC) who developed TLS within six days after initiating therapy with the tyrosine kinase inhibitor (TKI) pazopanib...
February 20, 2018: Investigational New Drugs
https://www.readbyqxmd.com/read/29464405/the-role-of-circulating-tumor-dna-in-renal-cell-carcinoma
#13
REVIEW
Paulo G Bergerot, Andrew W Hahn, Cristiane Decat Bergerot, Jeremy Jones, Sumanta Kumar Pal
Next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) is a novel technology that can complement tumor tissue NGS and has the potential to influence diagnosis and treatment of both localized and metastatic renal cell carcinoma (mRCC). ctDNA NGS is an attractive alternative to tumor tissue NGS because it circumvents the need for repeated, invasive tissue biopsies while providing a contemporary mutational profile of a patient's tumors. While the role of ctDNA NGS in non-small cell lung cancer and colorectal cancer is well established, studies of ctDNA NGS in mRCC are only hypothesis-generating to date...
February 20, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29464355/fdg-pet-ct-after-first-molecular-targeted-therapy-predicts-survival-of-patients-with-renal-cell-carcinoma
#14
Noboru Nakaigawa, Keiichi Kondo, Tomohiro Kaneta, Ukihide Tateishi, Ryogo Minamimoto, Kazuhiro Namura, Daiki Ueno, Kazuki Kobayashi, Takeshi Kishida, Ichiro Ikeda, Hisashi Hasumi, Kazuhide Makiyama, Narihiko Hayashi, Kimito Osaka, Kentaro Muraoka, Koji Izumi, Takashi Kawahara, Jun-Ichi Teranishi, Yasuhide Miyoshi, Yasushi Yumura, Hiroji Uemura, Tomio Inoue, Masahiro Yao
PURPOSE: We investigated prospectively whether18 F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG PET/CT) can predict the overall survival (OS) of patients with advanced renal cell carcinoma (RCC) previously treated by molecular targeted therapies. METHODS: Between 2009 and 2016, 81 patients who had received single molecular targeted therapies (43 sorafenib, 27 sunitinib, 8 temsirolimus and others) and were scheduled for second line molecular targeted therapies for advanced RCC were enrolled in this prospective study...
February 20, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29464274/percutaneous-microwave-ablation-for-local-control-of-metastatic-renal-cell-carcinoma
#15
Kimberly A Maciolek, E Jason Abel, Sara L Best, Hamid Emamekhoo, Sarah L Averill, Timothy J Ziemlewicz, Meghan G Lubner, J Louis Hinshaw, Fred T Lee, Shane A Wells
PURPOSE: The purpose of the article is to evaluate the safety and oncologic efficacy of microwave ablation for metastatic renal cell carcinoma (mRCC). MATERIALS AND METHODS: From September 2011 to December 2016, 33 mRCC were ablated in 18 patients using percutaneous microwave ablation. Sites of mRCC include retroperitoneum (n = 12), contralateral kidney (n = 6), liver (n = 6), lung (n = 5), adrenal gland (n = 5). Technical success, local, and distant tumor progression, and complications were assessed at immediate and follow-up imaging...
February 20, 2018: Abdominal Radiology
https://www.readbyqxmd.com/read/29464101/pneumatocele-during-sorafenib-therapy-first-report-of-an-unusual-complication
#16
Paloma Sangro, Idoia Bilbao, Nerea Fernández-Ros, Mercedes Iñarrairaegui, Javier Zulueta, J I Bilbao, Bruno Sangro
Sorafenib is a multi-kinase inhibitor and a vascular endothelial growth factor (VEGF) inhibitor approved to treat patients with advanced hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma. Its most common side effects are asthenia/fatigue, skin toxicity, diarrhea and arterial hypertension. Reported respiratory adverse reactions include dyspnea, cough, pleural effusion and hoarseness. The aim of this report is to describe for the first time the occurrence of pneumatocele in two patients treated with Sorafenib...
January 19, 2018: Oncotarget
https://www.readbyqxmd.com/read/29464030/under-expression-of-ck2%C3%AE-subunit-in-ccrcc-represents-a-complementary-biomarker-of-p-stat3-ser727-that-correlates-with-patient-survival
#17
Jordi Vilardell, Estefania Alcaraz, Eduard Sarró, Enric Trilla, Thaïs Cuadros, Inés de Torres, Maria Plana, Santiago Ramón Y Cajal, Lorenzo A Pinna, Maria Ruzzene, Juan Morote, Anna Meseguer, Emilio Itarte
Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive subtype of renal cancer. STAT3 pathway is altered in these tumors and p-STAT3 Ser727 is an independent prognostic factor for ccRCC. Protein kinase CK2 is altered in different types of tumors and overexpression of CK2α is considered predictive of bad prognosis and metastatic risk. CK2 subunits analyses in ccRCC samples showed increased CK2α/α' nuclear content in all cases, but decreased cytosolic CK2β (CK2βcyt) levels in the more advanced tumors...
January 19, 2018: Oncotarget
https://www.readbyqxmd.com/read/29463849/reconstruction-of-kidney-renal-clear-cell-carcinoma-evolution-across-pathological-stages
#18
Shichao Pang, Yidi Sun, Leilei Wu, Liguang Yang, Yi-Lei Zhao, Zhen Wang, Yixue Li
Although numerous studies on kidney renal clear cell carcinoma (KIRC) were carried out, the dynamic process of tumor formation was not clear yet. Inadequate attention was paid on the evolutionary paths among somatic mutations and their clinical implications. As the tumor initiation and evolution of KIRC were primarily associated with SNVs, we reconstructed an evolutionary process of KIRC using cross-sectional SNVs in different pathological stages. KIRC driver genes appeared early in the evolutionary tree, and the genes with moderate mutation frequency showed a pattern of stage-by-stage expansion...
February 20, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29463811/consequences-of-vhl-loss-on-global-dna-methylome
#19
Claire M Robinson, Francois Lefebvre, Betty P Poon, Aurelie Bousard, Xiaojun Fan, Mark Lathrop, Jorg Tost, William Y Kim, Yasser Riazalhosseini, Michael Ohh
In clear-cell renal cell carcinoma (ccRCC), loss of von Hippel-Lindau (VHL) tumour suppressor gene and reduced oxygen tension promote stabilisation of hypoxia-inducible factor (HIF) family of transcription factors, which promote changes in the expression of genes that contribute to oncogenesis. Multiple studies have demonstrated significant perturbations in DNA methylation in ccRCC via largely unclear mechanisms that modify the transcriptional output of tumour cells. Here, we show that the methylation status of the CpG dinucleotide within the consensus hypoxia-responsive element (HRE) markedly influences the binding of HIF and that the loss of VHL results in significant alterations in the DNA methylome...
February 20, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29463434/molecular-subtypes-of-clear-cell-renal-cell-carcinoma-are-prognostic-for-outcome-after-complete-metastasectomy
#20
Annelies Verbiest, Gabrielle Couchy, Sylvie Job, Laure Caruana, Evelyne Lerut, Raymond Oyen, Aurélien de Reyniès, Lorenzo Tosco, Steven Joniau, Hendrik Van Poppel, Dirk Van Raemdonck, Kathleen Van Den Eynde, Agnieszka Wozniak, Jessica Zucman-Rossi, Benoit Beuselinck
BACKGROUND: Metastasectomy is routinely performed in selected patients with metastatic clear-cell renal cell carcinoma (ccRCC) as an alternative to systemic therapy. In the absence of randomized trials, the benefit and best way of patient selection remain unclear. Earlier, we described four molecular ccRCC-subtypes (ccrcc1-4) that have a prognostic and predictive value upon first-line sunitinib or pazopanib. OBJECTIVE: Assess the prognostic value of ccrcc1-4 subtypes after complete metastasectomy...
February 17, 2018: European Urology
keyword
keyword
1723
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"